Benefits and risks of minocycline in rheumatoid arthritis

Drug Safety

Volumn 22, Issue 5, 2000, Pages 405-414

  Langevitz, Pnina ^a,b   Livneh, Avi ^a   Bank, Ilan ^a   Pras, Mordechai ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b HELLER INSTITUTE OF MEDICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

MINOCYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERPIGMENTATION; IMMUNOMODULATION; INTRACRANIAL HYPERTENSION; LEUKOPENIA; LIVER INJURY; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; RHEUMATOID ARTHRITIS; VERTIGO;

EID: 0034097452     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200022050-00007     Document Type: Review

References (108)

1. 1. Wollheim FA. Rheumatoid arthritis. In: Maddison PJ, Isenberg DA, Woo P, et al., editors. Oxford textbook of rheumatology. 2nd ed. Oxford; Oxford Medical Publications, 1998: 1018-31
2. 2. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990; 33: 1449-61
3. 3. Felson DT, Anderson JJ, Meeman RF. Use of short-term efficacy-toxicity trade-offs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials. Arthritis Rheum 1992; 35: 1117-25
4. 4. Morand EF, McCloud PI, Littlejohn GO. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 1992; 19: 704-8
5. 5. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994-1002
6. 6. Bartolomew IE. Isolation and characterization of mycoplasma (PPLO) in patients with rheumatoid arthritis, systemic lupus erythematosus and Reiter's syndrome. Arthritis Rheum 1965; 8: 376-88
7. 7. Brown T, Bush SW, Felts WR. In: Wohl MG, editor. Long-term illness: management of the chronically ill patient. Philadelphia: WB Saunders, 1959: 93-125
8. 8. Sanchez I. Tetracyclines treatment in rheumatoid arthritis and other rheumatic diseases. Brazil Med 1968; 82: 22-31
9. 9. Sande MA, Mandell GL. Antimicrobial agents. Tetracyclines. In: Gilman A, Goodman LS, Rall TW, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 7th ed. New York (NY): Macmillan Publishing Co, 1980: 1170-9
10. 10. Golub LM, McNamara TF, D'Angelo G, et al. A non-antibacterial, chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987; 66: 1310-4
11. 11. Golub LM, Ramamurthy NS, McNamara TF, et al. Tetracyclines inhibit tissue collagenase activity: a new mechanism in the treatment of periodontal disease. Periodontal Res 1984; 19: 651-5
12. 12. Golub LM, Suomalainen K, Sorsa T, et al. Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent 1992; 2: 80-90
13. 13. Greenwald RA, Golub LM, Lavietes B, et al. Tetracyclines inhibit human synovial collagenese in vivo and in vitro. J Rheumatol 1987; 14: 28-32
14. 14. Golub LM, Lee HM, Lehrer G, et al. Minocycline reduces gingival collagenonic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodontal 1983; 18: 516-24
15. 15. Golub LM, Wolf M, Lee HM, et al. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res 1985; 20: 12-23
16. 16. Rifkin RB, Colub LM, Sanavi R, et al. Effects of tetracyclines on rat osteoblast collagenase activity and bone resorption in vitro. In: Davidovich Z, editor. The biological mechanisms of tooth movement and craniofacial adaptation. Birmingham: EBSCO, 1992: 85-90
17. 17. Yu LPJ, Smith GNJ, Hasty KA, et al. Doxycycline inhibits type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J Rheumatol 1991; 18: 1450-2
18. 18. Pruzanski W, Greenwald RA, Street IP, et al. Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochem Pharmacol 1992; 44: 1165-70
19. 19. Vadas P, Pruzanski W, Kim J, et al. The proinflammatory effect of the intraarticular injection of soluble venom and human phospholipase A2. Am J Pathol 1988; 134: 807-11
20. 20. Bomalski JS, Lawton P, Browning JL. Human extracellular recombinant phospholipase A2 induces an inflammatory response in rabbit joints. J Rheumatol 1991; 146: 3904-10
21. 21. Breedveld FC, O'Brien JM, Brinckerhoff CE, et al. Suppression of collagen and adjuvant arthritis by a tetracycline [abstract]. Arthritis Rheum 1988; Suppl. 31: 588
22. 22. Sewell KI, Furrie E, Trentham DE. The therapeutic effect of minocycline in experimental arthritis: mechanism of action [abstract]. Arthritis Rheum 1991; Suppl. 33: S106
23. 23. Sewell KL, Fury E, Dynesius-Trentham R, et al. Evidence that minocycline suppress collagen and adjuvant arthritis by altering the expression of T cell derived, collagen-binding proteins [abstract]. Arthritis Rheum 1989; Suppl 32: S134
24. 24. Greenwald RA, Moak SA, Ramamurthy NSD, et al. Tetracyclines suppress metalloproteinase activity in adjuvant arthritis and, in combination flurbiprofen, ameliorate bone damage. J Rheumatol 1992; 19: 927-38
25. 25. El Attar TMA, Lin HS, Schulz, R. Effect of minocycline on prostaglandin formation in gingival fibroblasts. J Periodontal Res 1988; 23: 285-6
26. 26. Martin RR, Warr GA, Couch RB, et al. Effects of tetracyclines on leukotaxis. J Infect Dis 1974; 129: 110-6
27. 27. Thong YH, Ferrante A. Effect of tetracycline treatment on immunological responses in mice. Clin Exp Immunol 1980; 39: 728-32
28. 28. Kloppenburg M, Miltenburg AMM, Vendonk MYA, et al. Minocycline inhibits T-cell proliferation and interferon gamma (IFN-gamma) production after stimulation with anti CD3 monoclonal antibodies [abstract]. Br J Rheumatol 1992; 31 Suppl.: 41
29. 24. Langevitz P, Bank I, Zemer D, et al. Treatment of resistant rheumatoid arthritis with minocycline: an open study. J Rheumatol 1992; 19: 1502-4
30. 30. Wasil M, Halliwell B, Moorhouse CP. Scavenging of hypochlorous acid by tetracycline, rifampicin and some other antibiotics: a possible antioxidant action of rifampicin and tetracycline. Biochem Pharmacol 1988; 37: 775-8
31. 31. Van Barr HM, van de Kerkhop PC, Mier PD, et al. Tetracyclines are potent scavengers of the superoxide radical. Br J Dermatol 1987; 117: 131-2
32. 32. Brown TMcP, Bush SW, Felts WR. In: Wohl MG, editor. Long-term illness: management of the chronically ill patient. Philadelphia: WB Saunders, 1959: 93-125
33. 33. Sanchez I. Tetracycline treatment in rheumatoid arthritis and other rheumatic diseases [in Portuguese]. Brasil Med 1968; 82: 22-31
34. 34. Skimer M, Cathcart ES, Mills YA, et al. Tetracycline in the treatment of rheumatoid arthritis. Arthritis Rheum 1971; 14: 727-32
35. 35. Wright AL, Colver GB. Tetracyclines: how safe are they? Clin Exp Dermatol 1988; 13: 57-61
36. 36. Bardin T, Erel C, Cornelis F, et al. Antibiotic treatment of venereal disease and Reiter's syndrome in Greenland population. Arthritis Rheum 1992; 35: 190-4
37. 37. Bardin T, Schumacher HR. Should we treat postvenereal Reiter's syndrome by antibiotics? J Rheumatol 1991; 18: 1780-2
38. 38. Lauhio A, Leirisalo-Repo M, Lahdevirta J, et al. Double-blinded, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis with special reference to chlamidia arthritis. Arthritis Rheum 1991; 34: 6-14
39. 39. Breedveld FC, Dijkmans BAC, Mattie H. Minocycline treatment for rheumatoid arthritis: an open dose finding study. J Rheumatol 1990; 17: 43-6
40. 40. Kloppenburg M, Breedveld FC, Terwiel JPH, et al. Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1994; 37: 629-36
41. 41. Tilley BC, Alarcon GS, Heyse SP, et al., for the MIRA trial group. Minocycline in rheumatoid arthritis: a 48 week, double-blind, placebo-controlled trial. Ann Int Med 1995; 122: 81-9
42. 42. O'Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo. Arthritis Rheum 1997; 40: 842-8
43. 43. Bluhm GB, Sharp JT, Tilley B, et al. Radiographic results from the minocycline in rheumatoid arthritis trial (MIRA). J Rheumatol 1997; 24: 1295-302
44. 44. O'Dell JR, Paulsen O, Haire LE, et al. Treatment of early seropositive rheumatoid arthritis with minocycline. Four year follow up of a double-blind, placebo controlled study. Arthritis Rheum 1999; 42: 1691-5
45. 45. Langevitz P, Bank I, Livneh A, et al. Long-term experience with minocycline in patients with resistant rheumatoid arthritis (RA) [abstract]. Rheumatol Eur 1995; 24 Suppl.: D100
46. 46. Pruznaski W, Vadas P. Should tetracyclines be used in arthritis? J Rheumatol 1992; 19: 1495-6
47. 47. Trentham DE, Disenius-Trentham RA. Antibiotic therapy for rheumtoid arthritis: scientific and anecdotal appraisals. Rheum Dis Clin North America 1995; 21: 817-34
48. 48. Langevitz P, Livneh A, Bank I, et al. Minocycline in rheumatoid arthritis. Isr J Med Sci 1996; 32-4
49. 49. Alarcon GS. Minocycline for the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24: 489-99
50. 50. Paulus EH. Minocycline treatment of rheumatoid arthritis. Ann Int Med 1995; 122: 147-8
51. 51. Breedveld FC. Minocycline in rheumatoid arthritis. Arthritis Rheum 1997; 40: 794-6
52. 52. Kloppenburg M, Mattie H, Dauwes N, et al. Minocycline in the treatment of rheumatoid arthritis: the relationship of serum concentrations to efficacy. J Rheumatol 1995; 22: 611-6
53. 53. Malcolm A, Heap TR, Eckstein RP, et al. Minocycline induced liver injury. Am J Gastroenterol 1996; 91: 1641-3
54. 54. Golstein PE, Deviere J, Gremer M. Acute hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol 1997; 92: 143-6
55. 55. Beudreaux JP, Hayes DK, Mizrahi S, et al. Fulminant hepatic failure, hepatorenal syndrome and necrotizing pancreatitis after minocycline hepatotoxicity. Transplant Proceed 1993; 25: 1873
56. 56. Sorbi D, Thistle JR. Minocycline, an unusual cause of drug-induced lupus and autoimmune hepatitis. Am J Gastroenterol 1997; 92: 1732
57. 57. Hewak J, Teuyses G, Hunt RH. Minocycline induced hepatotoxicity presenting as autoimmune hepatitis: report of three cases [abstract]. Canadian J Gastroenterol 1996; 10 Suppl.: 57
58. 58. Min DY, Burke PA, Lewis D. Acute hepatic failure associated with oral minocycline: a case report. Pharmacother 1992; 12: 68-71
59. 59. Ovartlarnporn B, Kuluichit, Hiranniramal S. Medication induced esophageal injury: report of 17 cases with endoscopic determination. Ann J Gastroenterol 1991; 86: 748-50
60. 60. Puyana J, Urena V, Quirce S, et al. Serum sickness-like syndrome associated with minocycline therapy. Allergy 1990 45: 313-5
61. 61. Levenson T, Masood D, Patterson R. Minocycline-induced serum sickness. Allergy Asthma Proceed 1996; 17: 79-81
62. 62. Harel L, Amir J, Livni E. Serum sickness-like reaction associated with minocycline therapy in adolescents. Ann Pharmacother 1996; 30: 481-3
63. 63. Guillon JM, Joly P, Autran B, et al. Minocycline-induced cell-mediated hypersensitivity pneumonitis. Ann Int Med 1992; 117: 476-81
64. 64. Dupont C, Rouveix E, Chinet T, et al. Loffler's syndrome in a minocycline-treated woman. Ann Med Intern 1993; 14: 76
65. 65. Bentur L, Bar Kana Y, Livni E, et al. Severe minocycline-induced-eosinophilic pneumonia: extrapulmonary manifestations and the use of in vitro immunoassays. Ann Pharmacother 1994; 31: 733-5
66. 66. Sitbon O, Bidel N, Dussport C, et al. Minocycline pneumonitis and eosinophilia: report on eight patients. Arch Int Med 154: 1633-40
67. 67. Dykhuizen RS, Zaidi AM, Golden DJ, et al. Minocycline and pulmonary eosinophilia. BMJ 1995; 310: 1520-1
68. 68. Toyoshima M, Sato A, Hoyakawa H. A clinical study of minocycline-induced pneumonitis. Int Med 1996; 35: 176-9
69. 69. Bando T, Fujimura M, Noda Y, et al. Minocycline-induced pneumonitis with bilateral hilar lymphadenopathy and pleural effusion. Int Med 1994; 33: 177-9
70. 70. Dykhuizen RS, Legge JS. Minocycline induced pulmonary eosinophilia. Resp Med 1995; 89: 61-2
71. 71. Eisen D, Hakim MD. Minocycline-induced pigmentation: incidence, prevention and management. Drug Saf 1998; 18: 431-40
72. 72. Basler RSW. Minocycline-related hyperpigmentation. Arch Dermatol 1985; 121: 606-8
73. 73. Dwyer CM, Guddihy AM, Keer REI. Skin pigmentation due to minocycline treatment of facial dermatoses. Br J Dermatol 1993; 129: 158-62
74. 74. Okada N, Sato S, Sasou T, et al. Characterization of pigmented granules in minocycline-induced cutaneous pigmentation: observations using fluorescence microscopy and high performance liquid chromatography. Br J Dermatol 1993; 129: 403-7
75. 75. Schofield JK, Tatnall FM. Minocycline induced skin pigmentation. Br J Gen Pract 1993; 43: 173-4
76. 76. Katz J, Barak S, Shemer J, et al. Black tongue associated with minocycline therapy [letter]. Arch Dermatol 1995; 131: 620
77. 77. Hunt MJ, Salisbury ELC, Grace J, et al. Black breast milk due to minocycline therapy. Br J Dermatol 1996; 134: 943-4
78. 78. Sabrae RA, Archer CB, Harlow D, et al. Minocycline-induced discoloration of the sclerae. Br J Dermatol 1996; 135: 314-6
79. 79. Eedy DJ, Burrows D. Minocycline-induced pigmentation occurring in two sisters. Clin Exp Dermatol 1991; 16: 55-7
80. 80. Pepine M, Flowers FP, Ramas-Caro FA. Extensive cutaneous hyperpigmentation caused by minocycline. J Am Acad Dermatol 1993; 28: 292-5
81. 81. Hung PK, Caldwell JB, James WD. Minocycline-induced hyperpigmentation. J Fam Pract 1995; 41: 183-5
82. 82. Fraunfelder FT, Randall JA. Minocycline induced scleral pigmentation. Ophthalmol 1997; 104: 936-8
83. 83. Purdue B. An incidental autopsy finding of black thyroid associated with minocycline therapy. Med Sci Law 1992; 32: 148-50
84. 84. Meyerson MA, Cohen PR, Hymes JR. Lingual hyperpigmentation associated with minocycline therapy. Oral Surg Oral Med Oral Phathol Oral Radiol Endodontics 1995; 79: 180-4
85. 85. Parkins FM, Furnish G, Bernstein M. Minocycline use discolors teeth. J Am Dent Assoc 1992; 123: 87-9
86. 86. Eisen D. Minocycline-induced oral hyperpigmentation [letter]. Lancet 1997; 349: 400
87. 87. Rumback MJ, Pitcock JA, Palmieri GMA. Black bones following long-term minocycline treatment. Arch Pathol Lab Med 1991; 115: 939-41
88. 88. Moritz DL, Elewski B. Pigmented postacne osteomacutis in a patient treated with minocycline: a report and review of the literature. J Am Acad Dermatol 1991; 24: 851-3
89. 89. Leffell DJ. Minocycline hydrochoride hyperpigmentation complicating treatment of venous ectasia of the extremities. J Am Acad Dermatol 1991; 24: 501-2
90. 90. Butt A, Statham BN. Minocycline-induced hyperpigmentation of basal cell carcinomas. J Dermatol Treat 1998; 9: 39-42
91. 91. Wilde LJ, English III JC, Finley EM. Minocycline-induced hyperpigmentation: treatment with neodymium: YAG laser. Arch Dermatol 1997; 133: 1344-6
92. 92. Matsumura T, Shimizu Y. Fujimoto H, et al. Minocycline induced lupus [letter]. Lancet 1992; 340: 1553
93. 93. Farver DK. Minocycline-induced lupus. Ann Pharmacother 1997; 31: 1160-3
94. 94. Masson C, Pascaretti C, Capon F, et al. Minocyline-related lupus: a review of 23 definite cases [abstract]. Arthritis Rheum 1996; 39 Suppl.: 60
95. 95. Breedveld FC. Minocycline induced autoimmune disease: reply. Arthritis Rheum 1998; 41: 563-4
96. 96. Gordon FM, White MI, Herriot R. Minocycline-associated lupus erythematosus. Br J Dermatol 1995; 132: 120-1
97. 97. Gendi NST, Bawman SJ, Mowat AG. Lupus-like syndrome in patients treated for acne. Br J Rheumatol 1995; 34: 584-5
98. 98. Quilty B, McHugh N. Lupus-like syndrome associated with the use of minocycline. Br J Rheumatol 1994; 33: 1197-8
99. 99. Byrne PAC, Williams BD, Pritchard MH. Minocycline-related lupus. Br J Rheumatol 1994; 33: 674-6
100. 100. Lauwerys B, Martin F, Mahri A, et al. Minocycline: a common cause of drug-induced lupus. Clin Rheumatol 1997; 16: 520
101. 101. Gresson J, Stillman MT. Minocycline-related lupus erythematasus with associated liver disease. J Am Acad Dermatol 1997; 36: 867-8
102. 102. Masson C, Chevailler A, Pascoretti C. Minocycline related lupus. J Rheumatol 1996; 23: 2160-1
103. 103. Alain E, Miller LC, Tucker LB. Minocycline-induced lupus in adolescents. Pediatrics 1998; 101: 926-8
104. 104. Elkayam O, Yaron M, Caspi D. Minocycline induced arthritis associated with fever, livedo reticularis and P-ANCA. Ann Rheum Dis 1996; 55: 769-71
105. 105. Alain E, Miller LC, Tucker CB, et al. Minocycline related lupus-like syndrome: possible association with antineutrophil cytoplasmic antibodies. Arthritis Rheum 1997; 40 Suppl.: 191
106. 106. Elkayam O, Levartovsky D, Brautbar Ch, et al. Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am J Med 1998; 105: 484-7
107. 107. Boyd I. Benign intracranial hypertension induce by minocycline. Curr Ther 1995; 36: 70-1
108. 108. Weller M, Klockgether T. Minocycline-induced benign intracranial hypertension [letter]. J Neurol 1988; 245: 55